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In recognition of 10 years of
stem cell research at Yale, we
have devoted this issue’s feature section to the Yale Stem
Cell Center. Elsewhere in the
magazine, you’ll find stories
about ways in which our faculty, residents, and alumni are
advancing medicine or exploring history.
Observing teenagers’ obsession with video games prompted
Lynn Fiellin, M.D. ’96, HS ’00, to
wonder whether she could harness that fascination to impart
messages about health behavior. Working with researchers,
designers, educators, and
community partners, she has
developed a game that puts
a virtual character into risky
situations involving HIV, tobacco,
and drug use.
By the time he got to medical
school, Eliezer Sternberg, M.D.,
had already written two books
about the mind. Now the firstyear resident at Yale New Haven

Hospital has written a third,
about how behavior that might
seem strange to most of us can
make perfect sense to others.
“Our brain is always trying to
create a narrative of our lives,”
says Sternberg.
Hair, writes Kurt Stenn, M.D.,
a pathologist and dermatologist who spent 20 years on the
School of Medicine faculty, has
affected culture, psychology,
and even global trade. When the
European beaver population was
decimated to meet the demand
for beaver hats, European
explorers and trappers crossed
North America in search of the
pelts. In his book, Hair, A Human
History, Stenn starts by explaining why humans alone, of all
primates, shed their body hair.
These and other stories await
you in Yale Medicine. We hope
you enjoy this issue.
John Curtis
Editor, Yale Medicine
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dialogue

		 A decade of stem cell
research at the School of Medicine
first named and described stem cells late in the
19th century. More than 100 years later, scientists continue to rely on
these cells to unlock puzzles of the origins of human development and to
advance clinical treatment for diseases that were once considered incurable. A decade ago, the Yale Stem Cell Center opened its doors to pursue
that field of research.
GER M A N BIOLOGISTS

Yale Medicine spoke with Dean Robert J. Alpern, M.D., Ensign Professor
of Medicine, about the importance of human stem cell research and why
much in the field remains to be explored.
Why did you decide to open the Yale Stem Cell Center in 2006? Stem cells represented
a new area in biology with extraordinary potential to transform medicine. Understanding human embryonic stem cells has provided insights into many areas of
biology, including development, tissue regeneration, and cancer. It is too early to
know the full impact that understanding stem cells will have on medical care, but
progress has been impressive.
Why is it important to study stem cells? Stem cells have enormous potential to replace
damaged tissue. Research on stem cells provides insight into development and
developmental anomalies. In addition, we are now learning that with many cancers,
it is the stem cells that are the real culprits.
Which aspect of stem cell research do you see changing most rapidly in the next five years?
There will be continuing progress on many fronts. We must perform high-quality
research that leads to a thorough understanding of the biology of stem cells so that
they can be used therapeutically with maximal efficacy and safety.

ROBERT J. LISAK PHOTO

Stem cell research became politicized early on, partly due to the use of human embryos.
Have we moved past the politics? If not, how can we? I am not sure that we have moved
past the politics. There will always be ethical issues related to human embryonic
stem cells and we must pay careful attention to these concerns. We should also keep
dialogues open across a diverse group of individuals, from physicians to bioethicists
to cell biologists, who contribute knowledge and guidance to the field.
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Better health
through video games
N I N E T Y-S E V E N P E RC E N T O F YO U N G A M E R I C A N S —

including the five children of Lynn E. Fiellin, M.D. ’96,
HS ’00—play video games. According to the Entertainment
Software Association, the industry’s top trade group,
155 million Americans play video games with names like
Call of Duty, Grand Theft Auto, and Madden NFL 15. What
if, thought Fiellin, associate professor of medicine (general
medicine) and in the Child Study Center, she could harness that fascination with video games to teach adolescents
to avoid risky behaviors that could lead to HIV infection or
drug addiction?
While there is a long-standing
debate about the negative
effects of video games (they’re
sedentary, they encourage
obesity, they can be addictive),
the use of games to promote
health is growing. Studies have
shown that video games can
deliver health promotion and
interventions, and pharmaceutical companies, nonprofits,
foundations, and the National
Institutes of Health are exploring these possibilities. With a
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grant from the National Institute
of Child Health and Human
Development, Fiellin has assembled a team of researchers, game
designers, community partners, and educators to create
PlayForward: Elm City Stories.
The tablet-based game consists of
16 hours of play in which teens
in after-school, school-based,
and summer programs create
a virtual character who faces
risky scenarios—like taking a
relative’s prescription pills—to
explore possible outcomes based
on their actions and how those
actions might affect their future.
Elm City Stories, along with
three other games designed to

prevent tobacco and marijuana
use, HIV infection in young
women, and substance abuse in
teens, emerged from the lab that
Fiellin created in 2009. play2PREVENT (p2P)
Now, Yale has launched the
Center for Health & Learning
Games, which will will house
the p2P lab and partner with
departments across the university and organizations
nationwide to create and test
additional games aimed at
changing health behaviors and
improving science, math, and
other skills. The center will also
offer training in game design
in these areas. “While other
schools have programs for developing games, this is the first I
know of at a medical school and
the first, I believe, that’s trying
to fuse best practices for learning games and games for behavior change, which are often
found in separate silos,” said Ben
Sawyer, co-founder of the game
consulting firm Digitalmill and
a pioneer in the field of “serious”
games—games designed for purposes other than entertainment.
Marientina Gotsis, co-founder
and director of the University
of Southern California Creative
Media & Behavioral Health
Center, a research unit between
the School of Cinematic Arts
and the Keck School of Medicine,
said that although some academic collaborations have produced games in health in the
past eight years, none have led
to the creation of formal centers
or research units.

JERRY DOMIAN PHOTO

Although newly established,
the center’s work is well underway. Fiellin and deputy director Kimberly Hieftje, Ph.D.,
associate research scientist in
medicine (general medicine),
have established partnerships
with pediatricians, emergency
room physicians, obstetrician/
gynecologists, and others. The
center is collaborating with Yale’s
math department, educational
games developer Yogome, and
Amplify, an educational services
company that is testing learning games in India in collaboration with The Global Education
& Leadership Foundation. The
center is also partnering with
Peer Health Exchange, a national
organization that teaches health
education to high school students,
to conduct implementation pilot
studies to examine the integration of the game into their curriculum. In addition, Fiellin and her
team will work with the Tobacco
Centers of Regulatory Science
(TCORS) at Yale and at USC,
modifying their PlayForward
game to collect data from teens
on their attitudes, perceptions,
and knowledge of e-cigarette and
other tobacco product use.
The center grew out of Fiellin’s
conviction that there is a need
both for games that foster learning and behavioral change and
for research that shows that this
approach works. It’s not enough
to develop a creative game with
educational content, as Fiellin and
her team found out when they
created Elm City Stories. They
hired a leading game design firm,

Schell Games of Pittsburgh, Pa.,
to help them develop the game.
While the partnership was successful from the start, both sides
found it challenging to develop a
game that would engage players
and spark behavior changes that
would lead to a reduced risk of
HIV infection. So they drafted a
series of game playbooks, guidebooks that incorporate established psychological theories
into the gameplay. For example,
minigames—games within the
larger game—encourage players
to consider their future goals and

aspirations, learn to assess situations and think ahead, acquire
knowledge (like debunking the
myth that you can’t get pregnant the first time you have sex),
navigate peer relationships, and
prioritize in order to maximize
long-term benefits. “Our work
is very much based in science,”
said Fiellin. “Just like any science
project, you need a lab manual to
help you get a good result.” Now
they use this approach for all of
their games, which they then test
in randomized controlled trials. “There have to be some data
behind this,” noted Fiellin. “You
wouldn’t want your child taking a
medicine that hasn’t been tested.”
The Yale center will build and
test prototypes and then present

Lynn Fiellin and a team of
researchers, designers,
community partners,
and educators have
created a video game
that will help teens
learn to navigate risky
scenarios like drug use.
Research shows, says
Fiellin, that this approach
can affect behavior.
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Since 2011, school
faculty and administrators have tried to make
things a little easier
for young scientists
with a Junior Principal
Investigator Retreat that
helps them build their
organizational skills.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.

Even irrational
behavior has its logic

the psychological constructs of
games as well as other topics.
Using technology to improve
access to care—especially with
such hard-to-reach groups as
adolescents is a powerful concept,
according to Linda C. Mayes,
M.D., Arnold Gesell Professor in
the Child Study Center, who has
worked with Fiellin on adapting
games for children. Access to
games that are well constructed
and engaging may be better yet.
“Playing a good game is like reading a good novel,” said Hieftje.
“It can have a lasting impact.”
—Jill Max

Strange behaviors may not be illogical,
says Eliezer Sternberg, a first-year neurology
resident. His new book explains that a
damaged brain may compensate in ways
that seem logical to the patient, if not to the
rest of the world.
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Schizophrenics who hear voices.
An otherwise rational teacher
who insists she was abducted
by aliens. A woman with multiple personalities.
Most of us, including many
physicians, would consider these
people “crazy.”
Eliezer J. Sternberg, M.D., a
first-year neurology resident at
Yale New Haven Hospital, begs to
differ. Their behaviors may
be strange, but they are not
necessarily illogical, Sternberg
wrote in his recently published
book, NeuroLogic: The Brain’s
Hidden Rationale Behind Our
Irrational Behavior.
“A lot of Oliver Sacks-type stories seem so crazy on the outside,”

WILLIAM K. SACCO PHOTO

ON LIN E E XC LU S IVES

them to game developers for
fi nal full development, in much
the same way that biotech companies manufacture drugs and
devices developed in academia.
“It will be a research and prototyping factory rather than a
full-fledged game factory,” said
Sawyer, who has worked with
Fiellin since the beginning.
The center will also provide
increased training around game
design as a structured educational experience. The p2P lab,
which will be incorporated into
the center, has already worked
with more than 25 interns and
trainees, ranging from high
school students to postdoctoral
associates. These activities will
be expanded, and discussions are
underway to develop classes on

he said. “But often, if you find
snatched from his studies. “I am
out exactly what the defect is,
good at doing a lot with a very
exactly the brain problem, it’s
little amount of time without losalmost as if their behavior is a
ing momentum,” he said.
logical compensation for a really
The book was released in early
unfortunate circumstance.”
of self. What appears delusional
January by Pantheon with a print
Take schizophrenia. Hearing
is the brain’s way of compensatrun of 25,000 copies and has been
voices is the ultimate in irratioing for a deficit or illness, he said.
reviewed in The Washington Post.
nality, but schizophrenics don’t
“Our brain is always trying to
After completing his trainrecognize the voices in their
create a narrative of our lives and
ing, Sternberg, who dedicated
heads as their own, Sternberg
give us a story, give us a history,
his book to his wife, Sharona,
said. Faced with the irrational,
give us a purpose,” Sternberg said. and their 2-year-old son, Alex,
their brains draw a logical, if false,
The 28-year-old Sternberg
wants to go into practice and do
conclusion: The voices are those of has been fascinated by the brain
research. He also plans to write
the FBI, or God, or aliens.
his entire life. NeuroLogic is
more books, possibly about epi“How would your brain explain not his first book. The Buffalo,
lepsy or comas.
that to you?” Sternberg said. “If
N.Y., native had already written
Physicians should speak
you are the kind of person who is
two volumes on the mind, the
more often to a popular audiparanoid about the government,
first when he was a 17-year-old
ence to prevent the spread of
then government paranoia might
high school junior, the second
such dangerous misinformation
overtake you. That would make
as an undergraduate at Brandeis
as unfounded fears about childsense to you and give you closure.” University.
hood vaccines, Sternberg said.
Schizophrenia is just one of
Driving him is the ques“People in medicine are really
many neurological disorders or
tion of how a mere collection of
good at talking to each other
phenomena—both mundane and
cells—the human brain—can have but not as good at talking to the
unusual—that Sternberg explains
consciousness and autonomy.
general public,” he said. “I think
in his book. He tackles everything “We are all made up of the same
that’s a big problem, because
from why we forget to buy milk
matter that everything else
some of the biggest speakers on
on the way home and whether
is,” Sternberg said. “But human
medical issues have no medical
visualizing golf improves your
beings are the only collections of
training and say things that are
score to whether someone can
matter that reflect on their own
really, really damaging.”
be hypnotized to commit murexistence. What is it that makes
—Christopher Hoffman
der and why people believe in
that possible?”
alien abductions. Along the way,
He wrote the first three chapSternberg discusses such obscure
ters of what became NeuroLogic
and unusual disorders as Anton’s
during a gap year he took from
syndrome, in which blind people
Tufts University School of MediTreating psychosis early
do not realize they have gone
cine to do research. Inspired
For those who think the current
blind. He explains how the damby the popular economics book
U.S. mental health care system
aged brain compensates in ways
Freakonomics, Sternberg wanted
passes muster, Joel Roberts prological to the sufferer, if not to the
to write a book for a general audiposes this question: “Do we tell a
rest of us.
ence that didn’t shortchange the
patient with stage 2 cancer to wait
A second theme is the mind’s
science of the brain. To his surand come back when it’s stage 4?”
relentless striving to make sense
prise, several publishers loved his
When a mental illness led his colof the world and maintain a sense
proposal. Once he had settled on a lege student son to the emergency
publisher, Sternberg finished the
book in his last year and a half of
medical school. How did he do it?
By composing most of the book
in 10- to 15-minute increments

»
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On September 11, 2001,
Melissa Thomas was
a sophomore at West
Point. Just over four
years later she was at
a forward operating
base north of Baghdad.
In January she told her
story as part of a new
lecture series, Student
Voices.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.
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room, Roberts, of Fairfield
County, Conn., researched treatment options across the country.
Roberts, whose name has been
changed to protect his family’s
privacy, found that most programs
targeted patients in severe, prolonged crisis.
According to Vinod H.
Srihari, M.D., associate professor
of psychiatry, few people receive
timely treatment after their fi rst
episode of psychosis. The reasons can include a combination
of factors related to the patient
or the family’s awareness of a
need for care, how to access
professional care, and a lack of
youth-oriented services.
Srihari wants to change
these norms. “Patients may
lack insight into their need for
treatment, or, as is common to
many youth, make poor choices
around seeking help,” he said.
He believes that savvy marketing via mass and social media
channels could help. Two teams
at Yale and Harvard are testing
this approach through a fiveyear clinical trial funded by the
National Institutes of Health.
The trial tests the ways in which
patients are recruited: traditional
referrals or a campaign that
includes media messaging, professional outreach, and a rapid
response to calls for help. In 2014,
the trial’s baseline year, both
teams recruited via tried-andtrue referrals from mostly traditional clinical settings.
Harvard Medical School’s
Prevention and Recovery in
Early Psychosis clinic serves as

Vinod Srihari believes that patients with psychosis often don’t receive the treatment they
need early enough. A new program will help
determine if a savvy marketing plan will help.

the trial’s control and continues
to recruit through referrals. At
Yale, Srihari’s team emphasizes
early detection through advertising—he hired a New Havenbased marketing fi rm, Red Rock
Branding, to pitch a local awareness campaign on psychosis, a
mental disorder that includes
hallucinations, paranoia, and
delusions.
The opportunity pushed Red
Rock’s founder, Glen McDermott,
and his team into uncharted territory. “Focusing on a small target
population—100 of 400,000—that
is confronting a confusing and
sometimes scary set of experiences that are often stigmatized
presents a communication challenge beyond the usual marketing
strategy,” McDermott said. The
campaign, called Mindmap, targets women and men ages 16 to 35
in the New Haven area who may
suffer from psychosis.
In February 2015, the Red
Rock team launched mindmapct.

org, a website with a quiz
designed to assess symptoms
of psychosis. Anyone who suspects they’re at risk can call for
a free screening by professionals
at Yale’s Specialized Treatment
Early in Psychosis clinic. If they
qualify, they can join the trial.
McDermott collects metrics
through the website, Facebook,
and Twitter to determine how
people arrive on the quiz page.
When potential patients call for a
phone assessment, the Yale team
verifies which channel led them
to the hotline. Recently Red Rock
began hiring “Mindmap activists” to help refine and deliver
the message, McDermott said.
This cadre will share their own
mental health journeys at events,
write blog posts, and lead local
workshops about psychosis.
Final results won’t be available for some time, but Srihari
has noted a correlation. Since the
campaign’s start, calls to the free
screening hotline at Yale climbed
to 150, a 65 percent increase
over the baseline year. Of those
evaluations, a total of 38 patients
enrolled in treatment at STEP.
What excites Roberts, a volunteer advocate for Mindmap, is the
campaign’s potential to reduce
the stigma of psychosis. Roberts
wants to rewind back to that dark
night on the psychiatric ward
with his son. “I wish he could
have heard from doctors and
nurses that these symptoms are
normal for your illness,” he said.
“What you are experiencing is
normal, and you will get better.”
—Kathleen Raven

a collection of recent
scientific findings

DID A KNOCK ON THE
NOGGIN DRIVE
HENRY VIII BONKERS?

C L O C K W I S E F R O M T O P : I S T O C K P H O T O S (3) , I N FA N T P H O T O C O U R T E S Y O F K ATA R Z Y N A C H AWA R S K A ; O P P O S I T E PA G E , W I L L I A M K . S A C C O P H O T O

In the last 10 years of his life, the English monarch suffered from memory lapses, fits of rage, uncontrollable
impulses, headaches, insomnia, and perhaps even
impotence. According to a paper published in the
Journal of Clinical Neuroscience, these symptoms may
have come from too much jousting. Yale researchers
studied Henry VIII’s letters and other sources of the
time to document his medical history and events possibly related to his ailments. (He died in 1547.) Their findings support the notion that traumatic brain injuries
from jousting may have caused the king’s problems.
Historians, said behavioral neurologist Arash Salardini,
M.D., co-director of the Yale Memory Clinic and senior
author of the study, point out that the king’s behavior
changed after a 1536 joust when a horse fell on him and
knocked him out. “It is intriguing to think that modern
European history may have changed forever because
of a blow to the head,” Salardini said.

GIRLS AT RISK OF AUTISM
MORE SOCIALLY AWARE

MAMMOTH
ON THE MENU?

AGING RISK TAKERS
STILL TAKE RISKS

Infant girls at risk of autism, a Yale School of
Medicine study has found, are more socially aware
than at-risk infant boys—they pay more attention
to people and their faces. This increased awareness
was linked to milder social impairments later on and
may provide increased access to critical social experiences in early development. In the study, the first
of its kind, 101 infants who have older siblings with
autism and 61 infants with no risk of autism watched
a video of a woman smiling and cooing while pointing to toys and making a sandwich. A team led by
Katarzyna Chawarska, Ph.D., associate professor in
the Yale Child Study Center and in the Department of
Pediatrics, then tracked what the children looked at
and for how long. Chawarska’s lab hopes to discover
why girls have this social advantage.

An anthropology professor’s curiosity has debunked
a myth about the main course at a 1951 dinner at the
Explorers Club in New York. The dinner in the Grand
Ballroom of the Roosevelt Hotel—which included Pacific
spider crabs, green turtle soup, and bison steaks—
boasted an entrée supposedly carved from the carcass
of a 250,000-year-old woolly mammoth that had been
preserved in glacial ice. Even some hungry explorers
were skeptical—many thought it was an extinct giant
ground sloth, Megatherium. By means of an explorer
who missed the dinner, leftovers found their way to the
Yale Peabody Museum of Natural History. Eric J. Sargis,
anthropology professor and curator of mammalogy at
the Peabody, along with Yale graduate students Matt
Davis and Jessica Glass, and Gisella Caccone of the Yale
Center for Genetic Analyses of Biodiversity, decided in
2014 to analyze the cooked meat’s DNA through mitochondrial gene sequencing. The verdict? Neither mammoth nor sloth, but green sea turtle.

People who take risks in their youth are more likely
to continue taking risks when they’re older, according to an analysis of more than 44,000 German
citizens published in the Journal of Personality and
Social Psychology. These findings, said Gregory R.
Samanez-Larkin, Ph.D., assistant professor of psychology and a co-author of the paper, suggest that
risk taking could be a personality trait that remains
stable throughout adulthood. Samanez-Larkin and
colleagues at the Max Planck Institute for Human
Development in Germany and the University of Basel
in Switzerland studied subjects ages 18 to 85 who
participated for 10 years in a cross-national study.
People’s willingness to take risks, the study found,
depends on both their age and the risky activity.
The inclination to take financial risks remains steady
until retirement age, while the willingness to trust
people doesn’t change with age.
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A decade of stem
cell research at Yale
ON T H E SECON D F LOOR OF T H E YA L E ST EM CEL L CEN T ER is a machine
that Haifan Lin, Ph.D., the center’s director, likes to show to visitors. Th is $1 million
metal box can do overnight what less than a decade ago would have taken hundreds
of scientists years to accomplish—sequence a human genome. Already, Lin says, this
3-year-old machine is showing its age. Newer machines are even faster.
The machine is crucial to the work to which Lin has devoted his life, the study of
stem cells. A decade ago, when the Yale Stem Cell Center was founded, this new field,
“the ultimate frontier in biology and medicine,” offered untold promise in any number
of areas. Stem cells could reveal the secrets of how human bodies develop in the womb.
Learning more about how stem cells differentiate and become bone, muscle, and other
tissues could yield clues to controlling diseases. Stem cells have been used to test new
drugs before they’re tried out on patients. And stem cells could generate healthy new
tissues and organs to treat disease without provoking an immune response.
Since its founding, the center’s scientists have transplanted biomedically engineered lungs and tracheae made from stem cells into mice. They have sought cures for
Parkinson’s disease in stem cell research. They have studied links between stem cells and
stroke. Scientists are trying to use stem cells to create retinal epithelial cells. Research into
cancer stem cells could yield a treatment that would stop the disease at its source.
The potential of stem cells seems limitless, and the Yale Stem Cell Center is poised to
pursue that promise.
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Haifan Lin believes that there is much to learn about
the basic science of stem cells. When he launched
the Yale Stem Cell Center a decade ago, he wanted to
understand the development and biology of stem cells.
“The inner working mechanisms of stem cells are still
poorly understood,” he says.

A chance
to lead
Connecticut lawmakers’ decision to fund
stem cell research reverberates today
by kathleen raven
photograph by robert lisak
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A chance to lead

On August 9, 2001, Milton Wallack
listened on the radio as then-President
George W. Bush announced plans
to halt federal funding for certain areas
of stem cell research. “I remember it
all too well. I’ll never forget that date,”
the co-founder of Connecticut Stem Cell
Coalition said. A close relative had just
been diagnosed with type 1 diabetes,
a chronic condition in which the
body’s immune system mistakenly
attacks and destroys insulin-producing
cells. Researchers thought stem cells
could one day replace these lost cells.
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Bush’s mandate—which forced scientists to rely on
just a few existing human embryonic stem (ES) cell
lines—threatened scientific progress. Researchers
prize human ES cells because they are easy to grow
in the lab, and have the potential to become almost
any cell in the body. Wallack, now a retired dentist
in Branford, but always an activist, felt something
had to be done.
He met with Yale’s Diane Krause, M.D., Ph.D., professor of laboratory medicine, cell biology, and pathology, and Wesleyan University’s Laura Grabel, Ph.D., the
Lauren B. Dachs Professor of Science and Society, two
researchers thinking of working with human ES cells
in the state at the time. Gradually, Wallack’s coalition
expanded to include academics, lawyers, and politicians. In 2005, Wallack asked Paul Pescatello, J.D.,
Ph.D., then president and CEO of Connecticut United
for Research Excellence, an organization formed to promote bioscience in the state, to become co-chair of the
Connecticut Stem Cell Coalition. Their goal? Convince
the state to provide funding for human embryonic stem
cell research. Pescatello, who now leads the Connecticut
Business & Industry Association’s (CBIA) Connecticut
Bioscience Growth Council (as well as the New England
Biotech Association), agreed. “We wanted to make it
clear that Connecticut would be a safe haven for stem
cell research,” said Pescatello, a lawyer who became a
lobbyist for the biopharmaceutical industry after he lost
his brother to glioblastoma.
Despite the controversy surrounding embryonic stem
cell research, Pescatello believed that a bipartisan legislative coalition would support it. Working with business
and economic development advocates, especially the lobbying team at the CBIA, Pescatello drafted the blueprint
for what became Connecticut’s stem cell statute. At the
time, only California and New Jersey had plans to provide
state funding for human ES cell research. Massachusetts’
policymakers were debating the issue, but they faced
pushback from the Roman Catholic Church, whose influence was decidedly less in Connecticut, Pescatello said.
By 2005, Wallack and Pescatello along with their team
were ready to take their legislation to the state capitol in
Hartford. The proposed bill permitted human embryonic
stem cell research and set aside state funding for it, but
banned any activity related to human cloning.

Professor of Medicine, and Carolyn W. Slayman, Ph.D.,
Sterling Professor of Genetics, professor of cellular and
molecular physiology, and deputy dean for academic
and scientific affairs, asked a strategic planning committee where the School of Medicine should strengthen
its research focus. “The medical school had faculty
members—some of whom knew each other, some who
didn’t—who worked with stem cells,” Slayman said.
“But nobody would have looked from the outside and
said, ‘Yale is a powerhouse of stem cell research.’
It just wasn’t true at the time,” she said. The committee
recommended creating a stem cell center. In 2005,
a search began for the new center’s director.
Haifan Lin, Ph.D., then a professor at Duke
University, stood out among potential candidates,
Slayman recalled. While other medical schools had
focused on disease-specific research, Lin suggested
that the field had far more to learn about the basic
biology of stem cells. “How can it be that at cell division (in stem cells), one daughter cell keeps all of its
potential, while the other starts off on a process of differentiation?” Slayman said, her eyes widening at the
memory of the tantalizing, yet incredibly basic science
question that faced the burgeoning field at the time.
Lin accepted the position.

Milton Wallack

“When we started
this in 2004, people
thought I was crazy
and they said,
		‘You’ll never get 		
this done.’

perfect timing
Around the same time that Wallack and Pescatello’s
team of lobbyists were meeting with state lawmakers,
newly appointed Dean Robert J. Alpern, M.D., Ensign
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A chance to lead

By late spring 2005, the Connecticut legislature’s
public health committee began reviewing the proposed
stem cell legislation. That committee’s co-chair, state
senator and now U.S. Sen. Chris Murphy, became
the bill’s key champion, Pescatello said. Former Gov.
M. Jodi Rell remembered very little resistance among
lawmakers. “The bill was written and drafted about
20 times, then scientific leaders came in to make their
case, and we decided this was the course we wanted
to take,” she said. “It was time to step out front.” On
June 15, 2005, Rell signed the act into law. The law
earmarked $100 million in state funding for stem cell
research, at a rate of $10 million per year through 2015.
Gov. Dannel P. Malloy recently extended stem cell
research funding for $10 million a year through 2018.
lasting impact
In 2015, researchers at the Georgia Institute of
Technology looked at how state funding had affected
stem cell research in the few states that had set aside
a large chunk of money in the mid-2000s. The team
compared California, Connecticut, Maryland, and
New York. “In both California and Connecticut, state
funding programs appear to have contributed to overperformance in the field,” they wrote in Cell Stem
Cell. Connecticut especially seemed to reap benefits.
Approximately 67 percent of human ES cell-related
articles published by researchers in the state acknowledged state funding, according to the study.
Essentially no scientists were studying human
embryonic stem cells in Connecticut in 2001, and now
more than 150 researchers are working on such projects with state funding, Wallack said. At Yale, more
than 30 labs work on human ES cell research today.
Both the medical school’s stem cell core labs and the
University of Connecticut-Wesleyan University Stem
Cell Core have relied on state funding. While Yale’s
core labs provide embryonic stem cell culture, genomic
analysis, and imaging services, the UConn core focuses
on induced pluripotent stem (iPS) cell technology, said
Marc Lalande, Ph.D., who has directed UConn’s Stem
Cell Institute in Farmington since its opening in 2007.
The result has been close collaboration among the three
universities in ways that complement one another,
Lalande said. “Since this is a state fund, we have had a
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great collaboration. We have retreats once each semester,” he said. “Diane and Haifan are good friends.”
In March 2009, President Barack Obama, by executive order, lifted some of the restrictions on federal
funding for human ES cells. One year later, UConn
scientists contributed four brand-new human ES cell
lines to the National Stem Cell Registry maintained by
the National Institutes of Health for use by all stem cell
researchers. Lalande pointed to the creation of ImStem,
a stem cell therapy biotech company founded at UConn,
and continued collaborations with Alexion, a biotech
that was started by a Yale professor that moved its
headquarters back to New Haven earlier this year.
Two years ago, the legislature approved a measure
that moved the responsibility of distributing state stem
cell research grants from the public health department
to Connecticut Innovations, a quasi-public organization that serves as a state venture capital fund and
lender. The Connecticut Stem Cell Program has been
renamed the Regenerative Medicine Research Fund.
This change reflects a broader trend in science, and
does not take away the focus from stem cell research,
Wallack said.
“When we started this in 2004, people thought I
was crazy and they said, ‘You’ll never get this done,’ ”
Wallack recalled. A self-described optimist who
“always sees the glass 110 percent full,” Wallack has
already set his sights on a concern that weighs on all
stem cell researchers who rely on state funding in
Connecticut: how to secure the next round of funding
after 2018. /yale medicine
Kathleen Raven is an associate editor at Yale Medicine.

One stem cell
or many?
Parkinson’s disease once looked like a poster child for stem
cell therapy. Researchers knew that the chronic illness
started when cells that produced the neurotransmitter
dopamine died. Without dopamine, such symptoms as muscle rigidity and tremors emerged. As early as 1990, a team in
Sweden transplanted dopamine-producing cells from human
fetuses into the brain of a male Parkinson’s patient. Two
months later, the patient’s right arm appeared less rigid, and
he could sleep through the night, the researchers wrote in
the journal Science. Transplanted brain cells, the trial showed,
could reverse some of Parkinson’s hallmarks. Two more
decades would pass before scientists found clues to suggest
why the therapy worked. In the meantime, a reliable cellbased therapy for Parkinson’s remains out of reach.
When D. Eugene Redmond Jr., M.D., professor of psychiatry and of neurosurgery, began researching Parkinson’s
in the 1980s, patients had only one main treatment option:
a pill called levodopa, or l-dopa, which the brain converts to
dopamine. The drawback? While effective early on, the drug
eventually stops working, and can cause awful side effects
like hallucinations. If a fresh supply of neuronal stem cells
began replacing dopamine in a tiny midsection area of the
brain, the symptoms could be eliminated and the disease
could be considered cured, Redmond said.
Thirty-five years ago, Redmond started his lab on the
Caribbean island of St. Kitts. Overrun with vervet monkeys,
the island provided Redmond access to primates that can
develop Parkinson’s symptoms in ways that closely mimic
symptoms in humans. The disease can be induced in monkeys by exposing them to the synthetic drug MPTP, a neurotoxin. It kills the dopamine-producing neuronal cells in the
brain—humans exposed to the drug also develop Parkinson’s
symptoms. In 1985, Redmond injected fetal dopamine neurons directly into the monkeys’ brains and they improved.
This evidence helped support clinical trials in humans that
would come later, including the Swedish study. Those neuronal cells, however, could not be grown in vitro, and the use of
fetal tissue was and still is controversial.
Redmond and his lab members then tried multiple
types of stem cells to see which could work as well as the
fetal tissue grafts. Recently, they tried induced pluripotent stem (iPS) cells. These cells, derived from a monkey’s
skin cell, can be reprogrammed to become stem cells, then
turned into dopamine neurons and injected back into the
same monkey. Researchers want to use iPS cells as therapy
in humans because the body is less likely to reject what it
recognizes as its own tissue.
Some monkeys that received iPS cells got better, but
not predictably or consistently. Redmond and colleagues

wondered whether they’d missed a piece of the puzzle: Were
they putting in the right type of dopamine neuron—the cell
that they had been transplanting over the years? Or perhaps
the transplanted cells were not receiving the correct signals—called growth factors—from surrounding cells.
Genetic sequencing technology could help answer
these questions. Historically, A9 dopaminergic neurons,
the ones predominantly lost in Parkinson’s disease, have
been grouped into a single cell class, said Montrell Demond
Seay, Ph.D., associate research scientist in psychiatry, who
works in Redmond’s lab. “If your transplanted neuronal
stem cell is not the one doing the real functional heavy lifting, then your replacement therapy will never work,” Seay
said. With the help of Sherman Weissman, M.D., Sterling
Professor of Genetics, and Jennifer Yang, M.D., Ph.D., associate research scientist in genetics, Seay has sequenced
about 200 neuronal stem cells from a single monkey. They
extracted RNA from the A9 dopaminergic neurons and
sent the material off for genetic sequencing. Next, a biostatistician will determine whether there are different A9
neuron cell types. Seay’s goal is to sequence 1,000 neurons
from five different monkeys. Seay hypothesizes that each
A9 cell subtype is linked to a particular function, and therefore to different Parkinson’s symptoms. In the future, cell
transplants may include only specific subtypes for a more
targeted therapy, he said.
Redmond’s lab is also trying to determine which growth
factors will guide the organization of neuronal stem cells
once they are transplanted. If developmental cues are
absent when neurons are transplanted into adult brains,
cells may not reach their designated target area. So far,
Redmond and his team have tested glial cell line-derived
neurotrophic factor (GDNF) as a possible instructional
guide for stem cells in monkeys. The stem cells took root in
the brains of 10 monkeys, they found, but after 11 months,
only a small number of cells had differentiated into adult
A9 dopaminergic neurons. To alleviate or cure Parkinson’s,
enough transplanted stem cells must survive to replace the
original dopamine cells that have died and organize themselves within the right place.
Earlier this year, Redmond harvested eggs from the
ovaries of 30 monkeys to use in another promising technique in stem cell research: somatic cell nuclear transfer.
Redmond and his team will place the nucleus of a skin cell
into an egg cell whose nucleus has been removed. The
modified egg cell will receive an electric shock to make
it divide and reproduce. Ideally, this single cell will form
a blastocyst, which contains stem cells. After changing
into the right type of A9 neurons, these cells could be
implanted into the brain of the monkey that provided
the skin cells. Since the cells would be immunologically
matched to the donor, enough cells might survive, and the
result would be a long-term cure. “A few human patients
treated with fetal dopamine cells have recovered and
stayed better for periods of 10 or 15 years. I think it’s fair
to say that there is proof of principle that this strategy
will work,” Redmond said. “Now we have to create exactly
the right cell to do the job reliably and permanently.”
—Kathleen Raven
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What are stem cells?
Every human being begins as an embryo consisting of a
small bundle of stem cells—cells that are born as blank
slates, and, when they receive the proper signals, turn
into the skin, hair, muscle, blood, and other tissues that
make up the human body. These toti- or pluripotent
stem cells start with the ability to become any type
of cell, but as the human body develops, they take on
specific tasks that narrow their ability to differentiate.
Five days after a fertilized egg gives rise to an embryo,
the embryo’s inner mass includes embryonic stem cells
(ESCs), which can become any type of cell. As stem cells
reach their adult or postnatal state, they are no longer
toti- or pluripotent, but may still differentiate into several types of specialized cells.

18

yalemedicine.yale.edu

Embryonic stem cells

Adult stem cells

Embryonic stem cells are pluripotent—they can become any type
of specialized cell and reproduce
indefinitely. ESCs are created
through fertilization but can also
be created through somatic cell
nuclear transfer: DNA from an
adult cell, like a skin cell, is placed
into an unfertilized egg whose
own DNA has been removed. That
new cell can become a blastocyst
(a 5-day-old embryo), which then
yields embryonic stem cells.

The term adult stem cells is a misnomer—everyone from newborns
to the elderly has these postnatal cells, which are also called
somatic stem cells. They reside in
the brain, eye, muscle, skin, bone
marrow, blood, and liver, selfrenewing throughout an organism’s lifetime and creating new
cells to replace old ones. Natural
adult stem cells are multipotent—
able to turn themselves into
several types of stem cells but not
as many as embryonic stem cells.

Induced pluripotent
stem cell
Scientists have learned to tweak
adult stem cells, reprogramming
them in the lab to make them
similar to ESCs in their ability to
differentiate. Induced pluripotent
stem cell lines are adult stem
cells that have been “walked
backward” and are as pluripotent
as ESCs but don’t require the
destruction of an embryo.

P H O T O/ I L L U S T R AT I O N C R E D I T

Both embryonic and induced pluripotent
stem cells have been used for gene therapy
and organ repair. At Yale, scientists have
bioengineered vascular tissue using stem
cells and are working with them to regenerate the lung and trachea. Cell-based
therapies could lead to treatments that
would repair injuries to the nervous system,
and understanding human embryonic stem
cells could reveal clues to treating cancer.
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Religion,
politics,
morality,
and
stem cells
Priests, presidents, and scientists have
debated for years the medical benefits
and moral dilemmas posed by stem cell
research, with no clear consensus.
by jenny blair
illustration by otto steininger
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Religion, politics, morality, and stem cells

It was standing room only
in the auditorium in the Anlyan
Center on April 3, 2003, when
actor Christopher Reeve came to
speak about stem cells. Famous
for playing Superman on the
screen, he lost the use of all
four limbs after a horseback-riding
accident in 1995, and had become
an activist supporting human
embryonic stem cell (ESC)
research. In his talk at Yale,
Reeve decried barriers to the ESC
research that he believed had the
potential to cure his condition.
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“It’s morally irresponsible not to allow research to
go ahead on all these fronts, with very strict ethical
guidelines,” said Reeve. He would not live to see this
area of research bear fruit. In October 2004, he died
of cardiac arrest.
Not everyone agreed with Reeve, however. Ethical,
political, and religious concerns have plagued stem
cell research since at least 1998, when researchers in
Wisconsin derived the first human ESC line. This area of
science may not only involve the destruction of human
embryos to harvest or test stem cells, but it also raises
concerns about such issues as human-animal chimeras,
cloning, and donor payment or consent. Yet stem cells
hold promise for treating patients with amyotrophic
lateral sclerosis, diabetes, spinal injuries like Reeve’s, or
other devastating conditions. The result: years of passionate debate that has reached no consensus, leading
to a patchwork ethical and legal status for the cells. In
the United States, state stem cell laws range from outright bans to encouragement and funding. Federal law
permits the research, yet does not fund experiments
that involve embryo creation or destruction. Promising
though it is, human embryonic stem cell research in this
country has proceeded in fits and starts.
protecting the embryo & egg donor
The year that Reeve spoke, stem cell research in
the United States was sputtering. Two years earlier,
President George W. Bush had announced that due to
concerns over embryo destruction, federal funds could
fund research only on existing lines.
Though the term stem cell includes ESCs as well as
other types of stem cells, including adult stem cells
found in fully formed organs, concerns about embryo
destruction have dominated the ethical conversation
since stem cells first appeared in labs, recapitulating
arguments about the personhood and moral status of
the embryo. Is the common practice of retrieving stem
cells from an excess fertility clinic embryo justifiable,
though that embryo be destroyed in the process? Some
say yes, if the knowledge gained could save lives.
Others, like Daniel Sulmasy, M.D., Ph.D., a University
of Chicago ethicist and former Franciscan friar who
served on New York State’s stem cell ethics board from
2007 to 2009, say human rights begin at conception.
That view makes embryonic destruction unethical and
proposes a moral distinction between letting embryos
die naturally and destroying them in the lab.
The creation of new embryos—a practice that made
headlines in 2014 when Oregon researchers announced

that they had created patient-specific ESCs via
“therapeutic cloning” with human eggs—also troubles
Sulmasy. Anyone who believes human life merits
respect from conception to natural death, he says,
should oppose the creation of new members of humanity just to use those lives. In this view, he says, “No
good end could justify that means.”
Since the 1973 Roe v. Wade decision that legalized
abortion, such embryo-centered ideas have influenced
federal policy. A two-year moratorium on funding
embryo research followed that Supreme Court case;
even after the moratorium was lifted, no federal funds
were forthcoming. In 1979, an Ethics Advisory Board,
born of the newly established congressional National
Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, approved experimentation on embryos up to 14 days postconception,
when the primitive nervous system arises. But despite
that recommendation, Congress soon blocked federal
funding for such research. The 1995 Dickey-Wicker
Amendment banned the use of federal funds for creating or destroying human embryos, a ban that remains
in effect today. In August 2000, the Clinton administration published guidelines that would have allowed scientists to use federal funds to buy cells extracted from
unused frozen embryos. A year later, before funding was
dispersed, President Bush overturned these guidelines
with his landmark announcement. It pleased no one.
“Neither side liked Bush’s attempt at a compromise
solution,” says Stephen Latham, J.D., Ph.D., director of
Yale’s Interdisciplinary Center for Bioethics, who formerly
served on Connecticut’s State Stem Cell Research Advisory
Committee and who is now a member of Yale’s Embryonic
Stem Cell Research Oversight Committtee (ESCRO). Those
opposed to embryonic destruction thought the government’s hands were unclean, Latham recalls. Those who
supported ESC research pointed out that the existing stem
cell lines were of poor quality. Advocates and patients like
Reeve seethed, and scientists, urged on by the president’s
Council on Bioethics, changed gears and sought nondestructive ways to obtain useful stem cells.
Although the federal government would provide
no funding for the research, it did not ban it. Some
states, like Arkansas, Indiana, and the Dakotas, did
ban the research, while others, like California and
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Connecticut, established funding and advisory committees. “We had this very sharp debate, but nobody
ever said ‘Let’s make this illegal,’ ” Latham says.
Money figures, too, into donor ethics. Sulmasy and
others worry that stem cell research or therapy could
lead to coercive payments to economically disadvantaged women for their eggs—a concern that becomes
more relevant in the wake of the 2014 therapeutic cloning
achievement, which could lead to any number of patientspecific ESC therapies. The National Academies of Science
disapprove of paying egg donors, though the ethics board
in New York State decided (after Sulmasy left) to approve
such payment from public research funds.
stem cells without embryos
In 2007, there came a long-awaited game-changer:
stem cells that didn’t require embryo destruction.
Scientists in the United States and Japan had walked
human adult skin cells back into an embryo-like state,
creating induced pluripotent stem cells (iPS cells),
a momentous discovery that changed the field. Nine
years later, Latham says, researchers are doing more
work with iPS cells, which are cheaper and easier
to procure than ESCs.
Alas, iPS cells didn’t do away with the ethical issues.
For instance, iPS experiments may make use of
ESCs as gold-standard comparisons, which means
embryo destruction.
Another line of research attempts to derive sperm and
eggs from iPS cells. In 2012, a Japanese group achieved
this science fiction-like result in mice, announcing that it
had created functional sperm from mouse skin cells; the
new sperm successfully fertilized an egg, which in turn
gave rise to healthy offspring. Needless to say, the prospect of doing such a thing in humans is unsettling.
Then too, iPS researchers soon faced new consent
issues. A major regulatory shift came in 2009, when
President Barack Obama revoked the Bush ban by
executive order, reintroducing federal funding for the
study of stem cells derived from excess IVF embryos
(though not for their derivation). Stem cell research
advocates praised the step. The Obama order, however,
included strict criteria relating to informed consent.
Were biological parents of donated embryos fully aware
of what might become of their donation?
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“Some of the lines that Bush’s NIH was willing to
fund turned out not to have good consent behind them,”
Latham says. New guidelines eventually banned funding for research on older cell lines derived from labcreated embryos, admitting only those derived from
fertility clinic extras.
Early iPS cells derived from commercially available
cell lines, too, are likely to have been done without
donor consent—as with Henrietta Lacks, whose famously
immortal cervical cancer cells became a cornerstone of
modern biomedical research, though she never consented
to their dispersal before her death in 1951.
“There are ethical concerns about derivation of iPS
cells,” says Sandra Alfano, Pharm.D., a co-chair of the
Yale ESCRO since its founding in 2006. “This idea of
review of provenance and whether there was adequate
informed consent, that’s probably the biggest part of
the job for ESCRO currently.”
Maurice J. Mahoney, M.D., J.D., the other co-chair,
adds, “We now insist that people be asked, ‘Is it all
right that a cell line that came from your body ends up
around the world, in many laboratories, and may be
sold, may end up in animal species, which means that
animal research is going on with cells from your body?’
… We push those issues now.”
These days, according to Latham, the ESCRO gives
extra attention mainly to research proposals that involve
mixing human ESCs with animal embryos in such a way
that the animal’s nervous tissue or its sex cells could be
affected. This addresses unlikely but nonetheless prevalent public concerns that a mouse could be neurologically
humanized in a way that could increase its suffering, or
that one with altered gametes might escape, reproduce,
and cause an unpredictable environmental effect.
no escaping the ethical questions
Yale’s ESCRO observes its 10th anniversary this June,
well into the era of stem cell clinical trials. Dozens
are now underway, thorny issues notwithstanding.
For any discussion of ethical restrictions on stem cell
research must also take into account the human cost of
such restrictions—something Reeve made clear in his
talk at Yale. Millions could die, he said, while scientists
look for a way to avoid the ESC moral quandary.
“To say that we should just work on adult stem cells
because we’ll get there [eventually], that’s not fair to the
people who are suffering from diseases like ALS,” Reeve
said. “We’re going to lose valuable time.” /yale medicine
Jenny Blair, M.D. ’04, is a frequent contributor to Yale Medicine.

Hair, mice, and how
cells regenerate
The human body loses billions of cells every day, but its
self-renewing supply of stem cells, which can become
any type of tissue, continuously replace those lost cells.
Researchers, however, understand little about how this
regeneration is sustained. Valentina Greco, Ph.D., associate professor of genetics, of cell biology and of dermatology, and principal investigator at Greco Lab, wants to get
to the bottom of it.
What enables normal tissue, which can harbor
mutated cells, to continue to regenerate as healthy tissue
and not become cancerous? Greco looks for the answer
in hair follicle stem cells in their niche—the microenvironment in which stem cells live. She studies them in the skin
of live healthy mice.
Greco and her colleagues Ann Haberman, Ph.D., assistant professor of laboratory medicine and of immunobiology, and David Gonzalez, M.H.S., a research associate at
Yale’s In Vivo Imaging Facility, adapted two-photon ﬂuorescence microscopy to visualize cells in live mice. Greco
can tag the cells she wants to follow in ﬂuorescent transgenic mice, and track them throughout their life cycle.
Observing these cells in their natural environment, Greco
hopes to identify the choices and behaviors of stem cells
that sustain normal tissue function even when mutations
are present.
A better understanding of normal cell regeneration
could help researchers predict when something will
go wrong. “We could capture the initiation of cancer
and understand how it emerges from normal tissue
growth,” Greco said. “This has tremendous
potential for cancer prevention.”
—Sonya Collins
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As an anesthesiology resident in Boston, Laura Niklason
watched as cardiac surgeons sought usable veins for
bypass surgery. That’s when she began working on
creating new blood vessels in the lab. Now, her work in
tissue engineering has moved on to the lung and trachea.

Organ in
a bottle
Laura Niklason works to
engineer organs as replacements
for those that fail.
by ashley p. taylor
photographs by robert lisak
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Organ in a bottle

On the windowsill of Laura Niklason’s
office is an unusual knickknack:
a clear glass jar like a jug turned on its
side with two cork-shaped stoppers
along its top, thin protrusions on both
ends, and, inside, a paper sailboat.
A ship in a bottle. The boat, stuck
in there, Niklason says, by a stir-crazy
grad student late one night in the
lab, is no miniature yacht. But inside
bottles like these, called bioreactors,
Niklason, Ph.D., M.D., the Nicholas
Greene Professor of Anesthesiology
and Biomedical Engineering,
builds structures that trump the
trickiest marine art project: blood
vessels, windpipes, and lungs.

28 yalemedicine.yale.edu

Niklason first had the idea to build organs in the lab
when, during her time as an anesthesiology resident in
Boston, she watched cardiac surgeons struggle to find
transplantable veins for bypass operations: “We ought
to be able to grow a new one,” Niklason remembers
thinking. She also has a doctorate in biophysics, and
was a postdoc in the lab of chemical engineer and
biomedical engineering guru Robert Langer, Ph.D.,
at the Massachusetts Institute of Technology. It was
there that she grew her first blood vessels.
She continued her vascular engineering research at
Duke University and founded a company, Humacyte,
to build replacement tissues for clinical use. It is now
testing engineered vessels for use in hemodialysis
patients. Since coming to Yale in 2006, Niklason has
expanded her tissue engineering work to the lung
and trachea. She has also been collaborating with
the core labs of the Yale Stem Cell Center, where she
has a secondary appointment. Stem cell technology
touches every area of her research. Eventually, she
hopes to use stem cells, which can differentiate into
many tissue types, as the cellular materials for all
of her engineered organs.
“She’s an amazing inventor,” says Haifan Lin, Ph.D.,
the Eugene Higgins Professor of Cell Biology; professor
of genetics; and of obstetrics, gynecology, and reproductive sciences; and director of the Yale Stem Cell
Center. “She’s a modern Renaissance woman.”
a bioreactor
Niklason’s initial framework for engineering a replacement artery was to take blood vessel cells from a patient
or animal, culture them on a tube-shaped biodegradable
scaffold, and then implant the engineered vessels into
the same patient or animal. To avoid immune rejection, the idea was to “make an engineered artery just for
that patient or just for that animal.” In the Langer lab,
her attempts to grow an artery this way failed for two
years—until she started pumping nutrient-rich
liquid (called medium) through the vessel as it developed within the bioreactor, causing it to expand and
contract as blood vessels do in the body. To set up a
blood-vessel bioreactor like the one in Niklason’s office,
a researcher takes a silicone tube, sews a scaffold of
biodegradable mesh around it, and threads it between
the glass container’s protruding ends. The researcher
then pipettes a solution of cells onto that scaffold. As the
cells grow around the tube, medium courses through
it, strengthening the developing vessel. Other tubes
for providing nutrients and gas exchange enter the

bioreactor through the stoppers on top, and the whole
thing is filled with medium and kept in an incubator
to control the temperature and atmosphere. Making a
blood vessel this way takes about two months. Near the
end of the growth period, the silicone tubing is removed,
and the vessel is suitable for implantation into the body.
In 1999, Niklason reported in Science that by using this
method, she had successfully implanted pigs with engineered arteries made from their own cells.
At Duke, Niklason tried the same approach using
vascular cells isolated from elderly patients, but ran
into problems. Because the patients’ cells were old,
they had limited lifespans—they stopped dividing
and became difficult to grow. Additionally, the tissues they spawned were not as sturdy as those derived
from younger cells. Niklason tried using gene therapy
to trigger a lifespan-increasing enzyme, with limited
success. “The cells lived longer, but they didn’t make
tissues that were mechanically more robust.”
Once at Yale, Niklason tried a new approach: differentiating stem cells into smooth muscle cells (SMCs),
a major component of blood vessels, and using them to
create arteries. These newly differentiated human cells,
unlike those from elderly patients, would be young
enough to work. In 2008, her lab reported that it had
created an engineered artery by differentiating bone
marrow-derived stem cells into SMCs and then coaxing
the cells to form a blood vessel as before.
Now her team is building arteries and other tissues with induced pluripotent stem cells (iPSCs). These
cells are created by taking such differentiated cells
as skin cells and treating them with certain factors
that convert them into stem cells. Since a skin biopsy
is an easier and less painful procedure than bonemarrow isolation, this method has clinical advantages.
Eventually, Niklason hopes, a doctor could take cells
from a skin biopsy, create patient-specific iPSCs, and
then differentiate those iPSCs into the tissue types
needed to make personalized replacement organs.
The technology is a few steps behind this vision,
however. “We can differentiate the cells from stem cells;
we can make smooth muscle cells fairly well,” says
Niklason, “but not well enough such that they create
arteries that are implantable and strong enough to function long term.”
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Organ in a bottle

Laura Niklason

“Stem cell science has just exploded in terms
of what we know over the last 20 years.
		 The building blocks and the tools that
we have at hand now are just so vastly different
			from what they were even 10 years ago.
Down another avenue of research, however, Niklason
realized that personalized organs weren’t always the
best choice. Beyond the problem of old cells, which stem
cell technologies could circumvent, there were the constraints of time. If you need a new blood vessel, Niklason
says, “you probably don’t have the luxury of sitting
around three or four months and waiting for me to grow
you a new artery. We started racking our brains about
how to solve this problem in such a way that we could
make a universal artery.” Her solution was something
called decellularization.
Our cells secrete proteins that form the scaffold on
which they live and move—the extracellular matrix.
Wash away the cells, and the scaffold remains; this
washing step is decellularization. Niklason washed
away the cells of her engineered blood vessels and
implanted those decellularized arteries into animal
models. The decellularized vessels, she found, worked
as well as transplanted native blood vessels—and with
no immune rejection. “I can take this tissue, and I can
implant it into any human, and it won’t be rejected
by the body because we’ve washed away the stuff that
came from somebody else.” Furthermore, the vessels
didn’t stay decellularized forever. Taking cues from
the extracellular matrix, “cells from the patient
infiltrate into this tissue and turn it into a living tissue over time.”
The hemodialysis graft that Niklason’s company is
currently testing is one such decellularized blood vessel. Hemodialysis grafts create a conduit between a
vein and an artery in the arm into which large-bore
needles can be inserted to transport blood to and from
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the dialysis machine. Such grafts are made with either
a patient’s own vein from elsewhere in the body or
from plastic, and they often fail. Phase III trials comparing Humacyte’s decellularized grafts to their plastic
equivalents are slated to begin this year. “My hope is
that we’ll be able to grow thousands of these tissues
that can then go out to hospitals and be implanted into
any patient who needs a replacement blood vessel of
this type,” Niklason says.
Niklason is also using decellularization to engineer
tracheae (windpipes). Unlike blood vessels, which are
flexible, the trachea—supported by rings of cartilage
surrounding the airway—is designed to resist collapse.
In Niklason’s engineered windpipes, which she has
tested in rats and primates, that function is served by
a metal stent on which the tracheal cells are grown.
“We’ve got a stent-tissue composite,” she says.
The cells that Niklason cultures in order to make
decellularized blood vessels or tracheae for patients
come from organ donors, but Niklason would like to
use stem cells instead. She envisions a “bank” of stem
cells that could be differentiated into various cell types
as needed. “If we had an infinite cell bank, that would
be wonderful in terms of the reproducibility of the vessels that we make,” says Niklason.
more complex tissues
The decellularization strategy worked with blood vessels and tracheae, Niklason says, because many of their
functions come from their physical architecture, which
remains when you strip away the cells. That is not the
case with such complex tissues as the kidney, heart,

and lung, Niklason says. “Their function is derived
from the cells that are there. … So if you strip the cells
away you have no organ function.”
It is for engineering and transplanting one such
complex organ, lungs, into rats that Niklason is perhaps best known. For that project, reported in a 2010
Science paper, she also used the technique of decellularization, but this time for a different purpose.
Instead of trying to engineer the many branching
airways and air sacs of the lung, she decided to take
a donor lung, wash away the cells, and use it as a
scaffold on which to regrow the recipient’s own lung
cells in a bioreactor that both pumped fluid through
the lung’s vascular system and used another pump to
make the lung “breathe.” Then, the recipients were
rodents, but the goal is, of course, to build customized
lungs for patients.
To reach that goal, the Niklason lab is counting on
iPSCs. The lung contains many “flavors of epithelium,” she
says, and growing enough of those various cell types from
lung tissue biopsies is difficult. Instead, she and her team
are developing tools to differentiate them from iPSCs.

It helps that her lab is right above the stem cell core,
the labs that specialize in producing human embryonic
stem cells and iPSCs. “We work with them constantly,”
says Niklason. As Niklason’s engineering approaches
turn more and more toward iPSCs, that collaboration is
bound to continue.
“Stem cell science has just exploded in terms of what
we know over the last 20 years,” says Niklason. “The
building blocks and the tools that we have at hand now
are just so vastly different from what they were even
10 years ago.” Then, scientists had just figured out how
to create iPSCs from mouse tissue. Now, Niklason is
using them to develop personalized engineered organs.
“It’s a very exciting time to be working in this area, and
I feel very fortunate.” /yale medicine
Ashley P. Taylor is a freelance writer in Brooklyn, N.Y.
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Embryonic
stem cells
and diseases
of the retina
by sonya collins
illustration by otto steininger
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Seeing begins with photoreceptors, the cells that convert light into signals that the brain translates into the
images that we see. Those photoreceptors’ lives depend
on a layer of cells at the back of the eye called the retinal
pigment epithelium (RPE). “You can think of RPE as a
nurse that keeps photoreceptors happy and functioning.
If RPE gets sick and dies, photoreceptors get sick and die,”
said Lawrence Rizzolo, Ph.D., professor of surgery (gross
anatomy) who also runs a lab in Yale’s Stem Cell Center.
“It happens the other way, too. If photoreceptors die, RPE—
not having photoreceptors to interact with—dies, too.”
As part of their day-to-day operations, photoreceptors shed some of their light-capturing membranes and
acquire new ones. RPE eats the discarded membranes,
clearing them from the eye. “If that doesn’t happen,
you get all this debris in the retina that isn’t degraded,
and retinal diseases occur,” Rizzolo said. Those diseases are some of the leading causes of blindness,
including macular degeneration, diabetic retinopathy,
and retinitis pigmentosa.
RPE’s critical role in maintaining the health of
photoreceptors makes this layer of cells a potential target for treatment of these blinding diseases of the retina.
Researchers in Rizzolo’s lab are using human embryonic
stem cells to bioengineer RPE and retinal progenitor cells
(RPCs). They hope one day to implant the cells and restore
sight to people with certain types of vision loss.
Animal studies have shown that implanting stem cellderived RPE in the eye in the early stages of disease could
replace host RPE and slow vision loss. But later in the
disease, the procedure does not yield the same benefits.
In order for RPE transplant to gain traction as a treatment
option, Rizzolo says, it needs to be available to patients
who have begun to lose some vision and are willing to
take the risk of surgery. “Suppose you see okay now, and
you’ll probably see okay for another 10 years, but then I
told you things are going to get worse, and if this procedure works, we’ll slow that down—but if it doesn’t work,
you could go blind tomorrow because, after all, it is still
surgery and a difficult one.”
That’s not the only challenge for Rizzolo and other
researchers. As embryonic stem cells differentiate to
become RPE cells, they need RPCs nearby to shepherd
them through the process and vice versa. For full function of both tissues, they need to co-differentiate.
To address this problem, Rizzolo is growing RPE
cells on a matrix alongside retinal progenitor cells. He
and other researchers still need to find a way to grow
this retinal tissue in a flat sheet that mimics a normal
human retina. “When you grow retinal progenitor

cells, they grow as tiny spheres that don’t undo
themselves when you transplant them,” said Rizzolo.
Because these light-sensitive cells, which don’t work
without physical contact with RPE, are trapped inside
those tiny spheres, RPE cannot keep them alive.
Rizzolo and his team have developed a gelatin-based
scaffold in which to suspend RPCs and present them to
RPE as a flat sheet. So far, the scaffold has allowed his
team to produce flat, sheet-like retinal tissue.
The question now is, if researchers implant the
retinal cells later in the progress of the disease, will
they still slow it down or better yet, reverse it? “Those
experiments are in progress,” Rizzolo says.
Rizzolo’s team and physicians at the Yale Eye Center
will try the procedure on a live pig who underwent retinal
laser burns that simulate macular degeneration. After surgery, the pig will undergo tests to reveal whether its eyes
have resumed normal communication with the brain.
“If the signal gets to the visual cortex in the back of
the brain, this will tell me that not only did I reinstate
circuits in the retina, but those circuits are sending information to other parts of the brain.” /yale medicine
Sonya Collins is a freelance writer in Atlanta, Ga.
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From spare
parts to
delaying
old age—
the promise
and future
of stem cell
research
by bruce fellman
illustration by otto steininger
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The promise of stem cells

Since their first therapeutic human
use in 1957, when Seattle physician
and future Nobel laureate E. Donnall
Thomas, M.D., attempted a bone
marrow transplant to treat leukemia,
stem cells—those miraculous
collections of cytoplasm and nuclei
capable of an astonishing amount of
cellular transformation—have offered
to medical researchers, doctors,
and the public alike the prospect
of curing intractable diseases and
crafting a storehouse of spare parts to
remedy all manner of tissue damage.
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In 2006, buoyed by a combination of $10 million from
the State of Connecticut and $80 million in university
funds, Yale created its own Stem Cell Center (YSCC) at
the School of Medicine and recruited Haifan Lin, Ph.D.,
a rising superstar in the research community, to lead
the fledgling effort.
“Ten years ago, we began the center with a vision for
what we might be able to do with stem cells, both in
terms of medical applications and helping resolve the
mystery of life,” says Lin. “I’m happy to tell you that
quite a lot has been achieved on both fronts.”
More than 89 research groups from 23 departments are gathered under the YSCC umbrella, and
their interests run the gamut from deciphering the
fundamentals of stem cell biology to developing the
best ways of using the cells to treat some of the worst
human scourges, cancer and heart disease among
them. Working with the highest of high-tech tools in
laboratories dedicated to genomics as well as to growing, imaging, and manipulating what Lin calls “the
mother of all cells,” scientists here are beginning to see
these investments pay off. They now have the ability to
make custom-tailored tissues and organs that, because
they’re made from an individual’s own stem cells,
are transplantable with much less risk of the body’s
immune system attacking them and causing rejection.
“YSCC researchers have pioneered this approach
to repair children’s broken hearts,” says Lin, highlighting work by Christopher K. Breuer, M.D., and
Toshiharu Shinoka, M.D., who developed techniques
in which stem cells harvested from the bone marrow of children born with heart ventricular or atrial
defects could be reprogrammed to transform into new,
fully functional blood vessels that were then used to
repair the heart defects. (The two doctors now head the
Tissue Engineering Program at Nationwide Children’s
Hospital in Columbus, Ohio.)
this isn’t science fiction anymore
The first successful operation using such stem cellengineered cardiac tissues took place five years ago at
Yale-New Haven Hospital, and offshoots of the techniques are under investigation to develop other replacement parts, from sections of the brain to new lungs.
“This isn’t science fiction anymore,” says Lin, noting that
400,000 people die each year from lung disease because,
to a large degree, “there aren’t enough donors.”
Much of this progress, however, would never have
been possible were it not for a fundamental breakthrough announced at the time the YSCC opened for

business. In 2006, Japanese researchers demonstrated
that such ordinary adult mouse cells as skin cells could
be reprogrammed to become nearly as malleable as
embryonic stem cells, and the same possibility was
shown in human adult cells the following year. This
discovery allowed researchers to work with stem cells
that had not come from aborted fetuses, thereby avoiding the fierce ethical and moral debates. The ability
to now use induced pluripotent stem cells—iPSCs, for
short—however, has given Yale scientists an almost
limitless supply of raw material for applied and equally
critical basic investigations.
reprogramming adult cells
The ability to reprogram an adult cell so that it functions like an embryonic one is “incredibly cool,” says
Diane S. Krause, M.D., Ph.D., the YSCC’s associate
director who works with bone marrow-derived stem
cells to understand their involvement in the development of certain kinds of leukemia and how such cells
might be used in therapies against cancer.
Krause, a professor of laboratory medicine, cell
biology, and pathology, explains that while iPSCs have
yet to make a jump into a hospital setting, there are
at least a couple of scenarios—gene therapy and organ
repair—on the horizon. In advanced cases of sicklecell anemia, for example, doctors attempt to treat the
condition with a bone marrow transplant that comes
from a close relative of the sufferer. A cure is possible,
says Krause, “but the patient is also very much at risk
for graft-versus-host disease, which is serious and can
be fatal. So what if you could take the patient’s own
stem cells, correct the genetic defect that we know
causes the disease, then induce them to make fixed
copies that we could now transplant back? With such
an autologous transplant, there would be little risk of
graft-versus-host disease.”
In the case of a heart attack, adult stem cells from
the organ could be induced to become, say, muscle
cells that can be transplanted to regenerate new functional cardiac tissue instead of the scarring that now
typically results when an infarct leads to oxygen deprivation and tissue death.
Another area in which stem cells could prove
important involves the liver, particularly in the case
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of accidental or deliberate acetaminophen overdoses,
which can kill enough cells to prove fatal. “The liver is
actually really good at regenerating,” says Krause, “but
there are some patients who have a transient problem with liver regeneration, and if they could just get
enough cells to function until their own liver restores
itself, they would be able to survive long term.”
An autologous transplant of iPSCs reprogrammed to
become liver stem cells could, in theory at least, keep
a patient alive long enough to enable the damaged
organ to regain its functionality. All this, of course,
is a promise for the future. “We know perfectly well
that we can use iPSCs to treat acute liver failure,” says
Krause. “But we don’t know how to make the cells
become functional lymphocytes, how to get enough of
them, and how to make sure they’re safe.”
the importance of basic research
That, says Lin, is where fundamental research comes
in. “We realized early on that we didn’t fully understand the inner workings of stem cells, and without
the knowledge of the molecules that make them tick
and make them quiet, we would never be able to harness their power and come up with rationally designed
therapies,” says Lin. “We’d just be guessing.”
Lin received his bachelor’s degree at Fudan University
in 1982 in his native China, and a doctorate at Cornell
in 1990. Starting in 1994 at the Duke University Medical
School, Lin focused on a bold but risky research area:
the vast stretch of the genome known as “junk DNA.”
A small percentage of the human genome—some 26,000
genes—is known to make messenger RNA molecules that
help code for proteins, says the researcher. “The rest was
considered useless,” Lin explained, “but that turned out
to be more because of technological limitations than reality. We just weren’t able to find where the genes were and
how they might affect development in model species and
in humans, so we dismissed them as unimportant.”
With improvements in molecular tools, including such revolutionary technologies as DNA deep
sequencing, a gene-editing method known as CRISPR,
and others being used and developed in the YSCC
core laboratories, Lin and others discovered that this
viewpoint was akin to saying that since most humans
lived in cities, the countryside no longer mattered. It
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turned out that this so-called noncoding stretch of the
genome mattered plenty. “Junk DNA is making millions of little RNAs that are very important for determining the fate of stem cells—for turning them on and
off at the right time,” Lin explains.
Learn to hit the start button effectively, and the
result can be a supply of spare parts. Learn to hit
the stop button, and the result might be the medical equivalent of the Holy Grail: an effective cure for
cancer. “Studying stem cells is not only important in
regenerative medicine,” says Lin. “We believe that the
fundamental insights we’re discovering will turn out
to be crucial in creating a kind of personalized medicine that can treat malignancies.”
Current cancer treatment, of course, is brutal, since it
can’t discriminate between actively dividing normal cells
and their out-of-control counterparts. But Lin is working with some of his fundamental RNA insights on stem
cell reprogramming and control to find medications and
techniques to better diagnose and conquer breast cancer.
Preliminary results from his lab suggest that the rogue
cells responsible for metastatic disease can be stopped
from migrating, and over the next decade, Lin feels that
such studies may lead to the rational design of “very targeted, much less harmful” therapies.
Stem cell research may point to something even
more astounding. “We are on the verge of learning how
to protect the genome from being damaged, and this
might enable us to figure out how to extend a healthy
life for a longer time,” says Lin, suggesting that “old age”
may, sometime in the not-too-distant future, need to be
redefined. “We’re very excited about the progress we’ve
made and the prospects of what’s to come. The whole
field is undergoing evolutionary change, and Yale is an
integral part of it.” /yale medicine
Bruce Fellman is a freelance writer in North Stonington, Conn.

Why do so few stem cells convert?
Nearly a decade ago, stem cell researchers learned how to
create a cell that mimics a human embryonic stem (ES) cell.
Today, scientists in labs routinely create what are called
induced pluripotent stem (iPS) cells by reprogramming adult
somatic cells. These iPS cells are prized because, like embryonic cells, they can become almost any cell type in the body.
But in a sample of 1 million adult somatic cells, only about
100, or 0.1 percent, will convert to iPS cells in the lab—a very,
very low efficiency rate, said Shanqin Guo, Ph.D., assistant
professor of cell biology. Researchers don’t know why this is.
“If we understand the general rules of when and how one cell
type changes into another then we should in theory, be able
to interconvert any other cell types,” Guo said.

Guo and her team have amassed thousands of live microscopy images of mouse adult cells turning into mouse iPS
cells. They’ve tracked converted iPS cells in reverse to detect
patterns that might hint at certain qualities adult cells have
before they convert to iPS cells. So far, Guo has found that successfully converted iPS cells begin dividing more rapidly while
they are still adult somatic cells. Now Guo wants to determine
which comes first: a mechanism that turns on in somatic cells
allowing them to divide more rapidly, or an inherent ability to
divide rapidly that activates a certain mechanism. After that
conundrum is solved, the exact molecular mechanism that
aids in iPS conversion might come into focus.
—Kathleen Raven
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capsule
clinical clerkship sites across
Connecticut had made it difficult to produce a show. A
second-year show marking
the end of a pathology course
took over as the main student production.
That show endured until

		 Longest-running
show on Cedar
Street ends after
		 more than 60 years
		 Student spoof of life at Yale Med
will re-emerge as a Fourth-Year Show
		

By John Curtis
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stop takes them to medieval

Class of 1996

“Medicine is just conjecture
and fraud. We are a highly
respected institution: The
Yale School of Magic!!”
The students continue
through key moments of
the 20th century, including
the birth of modern neurosurgery, rock and roll, the
civil rights movement, and
the admission of the first
African-American woman to
the medical school.
The climactic scene,
based on Star Wars, pits Sam
(played by Alyssa MitsonSalazar) against “Darth

Class of 2000

Class of 2001

Alpern” (played by Daniel
Barson) in a “Doc Off” duel for
the soul of the medical school.
“Between the consulting gigs
and all the talk of RVUs, it’s
become so clear that medicine
has become such a business,”
Sam tells Darth Alpern. “And
it seems that you’re doing a
great job running that business. But can we still call this
doctoring?”
In the end, Darth Alpern
promises to hold a Town
Hall on the subject and the
students find their way back
JOHN CURTIS PHOTOS, PROGRAMS COURTESY OF THE CUSHING/WHITNEY MEDIC AL LIBRARY

to Cedar Street. And the elusive answer to the question,
What was the most important day in the history of the
Yale School of Medicine?
“Where would Yale Med
be today without every day?”
asks Sam. “Without every
moment? Without … .”
On a screen in the background, a computer taps out
the letters T-O-D-A-Y.

OPPOSITE PAGE Producers of the
first student show, 1949’s fourth-year
production, “Four Years for What Follies,” typed their program on stationery.
Over time, the playbills became more
polished and the show titles were
not averse to puns and plays on other
titles. The Class of 1982 evoked Samuel
Beckett with “Waiting for Fallot,” a
reference to a congenital heart defect.
The popular Broadway musical comedy,
A Funny Thing Happened on the Way to
the Forum, inspired the Class of 1990.
When the Class of 1996 produced their
show, their playbill was designed to
look like TV Guide and asked “Docs on
T.V.? See p.2.” At the time, eight popular
television shows, including ER, Northern Exposure, and Dr. Quinn, Medicine
Woman, featured physicians.

ABOVE, PROGR AMS The Class
of 2000 took their title from a
popular TV show of the 1990s,
calling their production “The Rx
Files.” The plot had Agents Mulder
and Scully searching for the missing Cushing brain registry. James
Bond was the inspiration for the
Class of 2001’s “Live and Let Diagnose,” whose plot lines included
human clones and Y-agra, a drug
that compels medical students to
attend class.

ABOVE, PHOTOS This spring, the
Class of 2018 presented the last
second-year show, “Remediation.”
The plot had students traveling
through time to milestones in the
medical school’s history. Sophie
Chung (top) played Harvey Cushing,
M.D., in a scene called “Phantom of
the Operating Room.” No secondyear show would be complete
without a joke about the digital
rectal exam (bottom). A hapless
patient, played by Dharshan
Anandasivam, assumes the
position as Sam, played by Alyssa
Mitson-Salazar, prepares to
administer the exam during a
“Doc Off” with “Darth Alpern.”
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			From music to
medicine and back
A LIFELONG LOVE OF JAZZ and a desire to care

for society’s most vulnerable children have
sustained Eli Newberger throughout his career.
One night last December, Scullers
Jazz Club in Cambridge, Mass.,
was packed with national experts
on child abuse, Peace Corps
veterans, and book group buddies,
all there to honor Eli Newberger,
M.D. ’66, HS ’67, M.P.H., who sat in
perhaps his favorite spot on Earth—
on stage, cradling his beloved tuba.
Newberger, a renowned child
abuse expert as well as a fixture
in Boston’s jazz scene, was turning 75 the day after Christmas.
The club added a second show to
accommodate fans of his medicine and his music.
Kicking off an all-Gershwin
set with his group, Eli & the Hot
Six, Newberger told the crowd:
“The amygdala in the brain is the
center for our sensation of stress.
It sets off a cascade of hormones
and messages. This is also where
music enters our brain.” Not your
typical stage patter.
But then, Newberger’s not
your typical musician or pediatrician. Both pursuits have been
important to him throughout

42 yalemedicine.yale.edu

his life: In addition to establishing himself as an expert on child
abuse, he has released more
than 40 acclaimed jazz albums.
As a pediatrician, he’s testified
in prominent cases of child and
sexual abuse.
His path began at Yale College,
where he started in physics before
switching to music theory and
taking pre-med courses on the
side. By the time he graduated
in 1962, he’d decided to apply to
medical school and do music—
he’s played the tuba since he was
10—on the side. He graduated,
married Carolyn Moore, a flautist from Sarah Lawrence, and
the couple played with the New
Haven Symphony Orchestra
while he attended medical school.
The two would continue to work
together—for 30 years, the couple
collaborated at Boston Children’s
Hospital, where he was a physician chief and she was director
of research and training in the
Family Development Program.
After receiving his medical
degree, Newberger completed an
internship in internal medicine
at Yale-New Haven Hospital. But
the Vietnam War was raging,
and male doctors were required

ERIK JACOBS PHOTO

Throughout his life
and career, music has
sustained Eli Newberger
and helped him relieve
the stress of his work as
a pediatrician who has
offered his expertise in
child and sexual abuse
in high-profile criminal
trials. He relaxes by playing the tuba in his jazz
band, Eli & the Hot Six.
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As a high school student,
Sudhakar Nuti came to
Yale to learn anatomy
from medical students.
Last fall, he became
the ﬁrst graduate of the
Anatomy Teaching
Program to enter Yale
as a medical student.
Mary Bassett, M.D.,
M.P.H., New York City’s
new health commissioner,
talks about health inequities on the Department of Internal Medicine’s Global Health Day.
Full stories and event
photo galleries, as well
as other online-only
content, can be found
on our home page at
yalemedicine.yale.edu.

to register for the draft. The
Newbergers opposed the war, so
he applied to become a doctor in
the Peace Corps. In 1967, the couple moved to Upper Volta in West
Africa—now Burkina Faso—with
their 1-month-old daughter.
Newberger's stint in Africa
included working with impoverished mothers and children, and
led him to an interest in pediatrics and a residency at Boston
Children’s Hospital. As a resident,
he alerted the physician-inchief about “a worrying pattern
of rehospitalizations” of young
patients who had been reported
to child protective services.
Mandated reporting laws for suspected child abuse were new, and
the hospital staff wasn’t yet well
trained in recognizing such abuse.
Newberger was asked to find out
what other hospitals were doing.
He was just 29 years old
when he was asked to start a
child abuse unit at Children’s
Hospital. He had no experience
in the field, but Newberger’s
multidisciplinary team of doctors, nurses, and social workers
would become a national model.
In Boston, Newberger is best
known as the key prosecution
witness in the trial of Louise
Woodward, the British nanny
convicted of second-degree
murder in the death of 8-monthold Matthew Eappen in 1997.
Newberger testified that Matthew
was the victim of violent prolonged shaking, and that a blood
clot on his brain and a fractured
skull indicated that he had also
been slammed against a hard

Pearls of wisdom from
years on the wards

surface. Newberger also offered
his expertise on the effects of
abuse on children and their families during the sex abuse crisis in
the Archdiocese of Boston.
Today, the Newbergers are
semi-retired from the health
care field, but perform with Eli
& the Hot Six, in which Carolyn
plays the washboard. They have
a second home in the Berkshires,
where he writes music reviews
for the online site The Berkshire
Edge, and Carolyn, a gifted artist, illustrates them. The booklet
that accompanies the Hot Six’s
new CD, “Contemporary Classic
Jazz,” features Carolyn’s real-time
sketches of the performers.
The nexus of medicine and
music has sustained Newberger
throughout his career. Starting
in 1971, he and his band had a
regular Thursday night gig at a
suburban Boston pub. It was the
same year he started his Thursday
outpatient clinic, and he’d go
directly from the hospital to the
pub. “I had 30 years of stress
overload that was compensated
by performing jazz,” he said. “The
positive sensations in experiencing music are processed in the
same midbrain organs as those
that bring us to hyperalert in the
face of severe danger. The music
enabled me to do what’s most
challenging—and for many physicians in child abuse work—vexatious, caring for the victims and
their families, offending and
unprotecting parents included.”
—Bella English
Bella English is a reporter for The Boston Globe,
where a version of this article first appeared.
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In the fall of 1960, Lewis
Landsberg, M.D. ’64, HS ’70,
fi rst set eyes on the legendary
Paul Beeson, M.D., at a Saturday
morning medical ground rounds.
As Beeson entered Fitkin
Amphitheatre, the renowned
chair of internal medicine at
Yale took his usual seat in the
fi rst row on the right-hand
side of the lecture hall. Then
the learning began with the
clinical presentation of real
patients, who were frequently
in attendance. It didn’t take
but a couple of months for
Landsberg, then a fi rst-year
medical student, to realize that
he was no longer interested in a
career in psychiatry.
“Internal medicine at Yale
was exciting and compelling,”
said Landsberg about his choice
of specialty. “Intellectually
challenging, it was an area of
medicine I wanted to pursue.”
And indeed he did—becoming a
leader in his field and reaching
the highest ranks of academic
medicine.
Landsberg’s leadership roles
took him from Yale to Harvard
and finally Northwestern, where
he served as dean of the medical
school. During almost half a century of experience as a clinician
and teacher, Landsberg distilled
his knowledge into aphorisms
to teach budding physicians
the art and science of caring
for ill patients. He often offered
his “pearls” of clinical wisdom
on rounds and during morning

JIM ZIV PHOTO

under the mentorship of Philip
K. Bondy, M.D. Landsberg then
completed a research fellowship at the National Institutes
of Health in the laboratory of
Nobel laureate Julius Axelrod,
report, but he never wrote them
Ph.D., before returning to Yale as
down—until recently.
a junior faculty member. In 1972,
Prompted by colleagues and
former Yale professor Franklin
students, Landsberg spent a
H. Epstein, M.D., moved on to
little over a year recalling from
Harvard Medical School and
memory the many “pithy statelured Landsberg away from his
ments of fact” now featured
alma mater. During his 18-year
in the new book On Rounds:
tenure at Harvard, Landsberg
1000 Internal Medicine Pearls—
served as chief of the Division of
Clinical Aphorisms and Related
Pathophysiology (Wolters Kluwer, Endocrinology and Metabolism.
Leaving Boston for Chicago in
2016). The pocket-sized book
1990, he became chair of internal
presents the pearls by organ
medicine at Northwestern and a
system for easy reference, feadecade later, dean.
turing information Landsberg
In 2007, Landsberg stepped
deemed most critical to developdown from the top spot to launch
ing mature clinical judgment. For
the Northwestern Comprehensive
example, a favorite Landsberg
Center on Obesity. Running the
aphorism, “Never let a single labcenter has given him the oppororatory result dissuade you from
tunity to tackle the problem
a diagnosis strongly suggested by
of obesity with novel clinical
the weight of the clinical findapproaches and advancements in
ings,” reminds inexperiencedresearch, including his own. He
to-seasoned clinicians not to rely
has long conducted studies in the
solely on the numbers.
areas of catecholamines, dietary
The book also includes a few
intake and the sympathetic nerfaux pearls to keep readers on
their toes. For example, a widely vous system, and obesity and
hypertension. It also has afforded
held belief is that antibiotics
him the time to return to teaching
should be avoided in cases of
medical students and residents—
Salmonella enteritis because
and sharing his pearls.
treatment may result in a proLandsberg dedicated his book
longed carrier state. Not true,
in part to his intern group at Yale,
according to Landsberg. “The
“whose friendship has been a lifepoint is to be aware,” he said.
long treasure.” He also acknowl“Not everything people tell you
edged some of the many mentors
is correct.”
who helped shaped his career,
A master clinician in his
including Yale professors Beeson,
own right, Landsberg learned
Bondy, and Epstein. Additionally,
from the very best. A member of
Beeson’s last internship group,
known as the Iron 'Terns, the
native New Yorker went on to
become chief resident in medicine at Yale-New Haven Hospital

Over the course of more than 50 years as
a clinician, Lewis Landsberg has distilled
his knowledge into aphorisms that he
shared with younger doctors. Now he has
published his pearls of wisdom in a book.

he thanked his son Judd, a 1996
graduate of Yale’s medical school,
for “many fruitful discussions” as
the book came together.
Released last September,
the book has already started
reaching its target audience. At
Northwestern, the Department
of Medicine distributed it to
residents and faculty members.
Internal medicine residency program director Aashish Didwania,
M.D., describes it as “extremely
accessible and clinically relevant,”
and containing pearls not easily
found in textbooks. Chief medical
resident Natasha Nichols, M.D.,
often uses Landsberg’s book after
a heavy call day to look for teaching points to discuss on rounds.
While he doesn’t carry the
book in his white coat, secondyear resident Andrew Davis, M.D.,
appreciates having Landsberg’s
tried-and-true observations close
at hand. “The book taps into how
a master clinician thinks, which is
one quality that makes it unique.”
—Cheryl SooHoo
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question and answer

			 How Haifan Lin
pushes the envelope
		 on stem cell research
WHEN HAIFAN LIN, PH.D., the Eugene Higgins Professor of Cell

Biology and founding director of the Yale Stem Cell Center,
arrived in New Haven in 2006, Dean Robert J. Alpern, M.D.,
Ensign Professor of Medicine, gave him a straightforward
albeit Herculean mission: Build a top-notch stem cell
research center. Lin took note of School of Medicine
researchers whose experiments had already delved deep
into stem cells, and asked them to join the center as affiliates.
Over the next decade, Lin establish-

As Lin recalled the center’s con-

ed training platforms and programs

tributions to stem cell science, he

to help more than 40 labs launch

highlighted its breakthroughs in

research projects on human embry-

basic biology and innovations in

onic stem cells and induced pluri-

translational science. In 2010, Time

potent stem cells (iPSCs). He also

magazine featured lab-grown lungs

recruited a handful of fast-rising

created by Laura Niklason, Ph.D.,

stars to the center and recruited

M.D., the Nicholas Greene Professor

others to Yale. Now, Yale’s 91 stem

of Anesthesiology and Biomedi-

cell researchers collaborate, trou-

cal Engineering, as No. 12 out of

bleshoot, and problem solve across

50 important inventions that year.

the campus—not just within the

(Apple’s iPad was No. 34 that year.)

brick walls of the center on Amistad

For Lin, who began researching

Street. The center acts as a hub

stem cells in fruit flies as a postdoc

rather than a hierarchy, and that has

at the Department of Embryology at

encouraged spontaneity and cre-

the Carnegie Institution for Science

ativity within research experiments,

in Baltimore Md., in the 1990s, the

Lin said.

field has advanced at warp speed.
“Using stem cells to cure diseases is
not a promise of tomorrow, it has
begun as a reality of today,” he said.

{ To nominate a subject for Q&A, contact

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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Q&A WITH

Haifan
Lin

What aspect of stem cell
basic science research
excites you most right now?

by discovering more about

We are exploring new ter-

the fundamental principles
and theories around stem
nucleotides that make up a

cells, and then apply this new

a person who favors a conser-

cell division. For example,

gene are beads on a necklace.

knowledge to translational

vative approach to stem cell

Andrew Zhuo Xiao, Ph.D.,

Most genes make RNAs that

and clinical research.

research does not have a prob-

assistant professor of genet-

are 1,000 beads (nucleotides)

ics, recently discovered a

or longer. But these genes

new modification of the DNA

make tiny RNAs that have

structure as a mechanism of

only 24 to 31. These genes

lem turning his or her own

there are molecules modify-

junk DNA. People thought

ing DNA to determine which

they had no purpose, but I

Bone marrow transplants
were for a long time the only
stem cell therapy approved
by the Food and Drug
Administration. Why don’t
we have more approved
therapies? Several other stem

genes are active or inactive.

believed they existed for a rea-

cell-related therapies have

system as our own cells, and

Xiao found this new kind of

son. The latest research from

recently been approved by

so you do not have to worry

modification to be important

my lab suggests that these

the FDA for clinical trial. For

about our bodies rejecting

for embryonic stem cells. He

RNA-making genes could

example, Yale-New Haven

them after transplanta-

also discovered a specific pro-

be closely related to cancer.

Hospital has the first FDA-

tion. The third is that we can

tein responsible for regulating

Normally, these genes are

approved clinical trial for

now obtain all types of cells
from our iPS cells instead of

gene regulation. DNA car-

are located in the part of the

ries genetic information, but

genome that used to be called

ordinary cells, such as skin
cells, into stem cells for treatment. The second advantage is
that iPS cells from a person’s
body can become various
types of tissue cells that will
be recognized by our immune

this modification of DNA. If a

expressed only in reproduc-

a bone marrow cell-based

stem cell lacks the modifica-

tive cells (egg or sperm). But

therapy for congenital heart

directly from our body, which

tion, then its fate will change.

we found that regular cells in

defects, which has been very

is often impossible. This way

Researchers didn’t know

the body, called somatic cells,

successful. These new approv-

we can study the causes of

this form of gene regulation

become cancerous when some

als reflect the rapid progress of

diseases in our tissue cells and

existed in stem cells or any

of these genes are expressed.

the field. We are still working

try out different treatments

mammalian cells. This is one

We have preliminary evidence

on the best and most reliable

without using or hurting our

example of how we are push-

to show that if you remove

methods for growing millions

bodies.

ing the envelope of knowledge

the expression of these genes,

of stem cells outside the body

not only on stem cells, but

then it may be possible to slow

for therapeutic purposes. A

also on basic biology.

down cancer development.

stem cell transplant requires

need to find a way to amplify

Stem cells exist throughout the human body in all
organs and tissue, but are
rare and difficult to find. Why
is that? Because they are

stem cells without changing

the most important cells, so

their properties.

they exist in extremely small

many cells—just isolating the

Tell us about your own
research. In one area of my
standing a new class of genes

Many universities and colleges have stem cell research
centers. How is Yale’s different? Many stem cell

research, I focus on under-

cells is not enough. We also

that produce tiny RNAs

centers are heavily focused

instead of proteins. In my lab,

on the translational side.

we have cloned over 10 mil-

This strategy has its reasons

lion tiny RNAs, a number

and strengths. However, we

that is about 400 times more

started by exploring the basic

Why was Shinya Yamanaka’s
discovery of induced pluripotent stem (iPS) cells in Japan
in 2006 so important?

than the total known number

science to better understand

It offered three huge advan-

or stem cell, is hiding, usually

of genes. Imagine that the

what is going on behind the

tages. The first is ethical. Even

toward the back, in a fortified

development and biology of
TERRY DAGRADI PHOTO

Kathleen Raven

stood. Our strategy is to start

ritory within the molecular
mechanisms that govern stem

CONDUCTED BY

cells are still poorly under-

numbers and often hide in the
most protected locales. Like
on a battlefield, the soldiers,
or regular cells, are on the
frontline. But the commander,

shelter. That’s why we’ve had

stem cells because the inner

to use special methods in the

working mechanisms of stem

lab to identify stem cells.
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book review
Western culture. English
herders raised the best
wool, and competed with
Flanders to turn it into
cloth for the world. The
wool trade created the for-

from cold climates provide the

tunes of such bankers as the

best bow hair.) Percussionists

Florentines, whose patron-

strike drums using hammers

age of Michelangelo gave us

cushioned with sheep’s wool

the Sistine Chapel's painted

felt. Paint brushes contain

ceiling. The descendant of

hair from pigs, squirrels, bad-

an English wool merchant

gers, and cows.

a sign in the window of

		 Hair and the
course of human history
By Cathy Shufro

Research into hair could
help solve fundamental sci-

his “fair stone house” that

entific problems, Stenn says.

exulted, “I thank God and

For instance, scientists do not

ever shall/It is the sheepe

fully understand what causes

hath payed for all.”
The hair of the beaver

stem cells in the mid-follicle
to differentiate into hair shaft

also changed the course of

cells. “If we understood the

history. By the 16th century,

hair follicle,” says Stenn, “we

beaver-felt hats were all

would probably get a good

the rage in Europe. Hatters

understanding of the regen-

who used toxic mercury in

eration process of the lung

the felting process devel-

and the kidney and the eye.
Biology is so conserved that

The hair on our heads is just

a meltdown (that is, brain

oped dementia—thus, the

the departure point for this

death) at 107 degrees

expression “mad as a hatter.”

the law of one organ system

wide-ranging book by Kurt

Fahrenheit. Just 10 or 20 min-

Nonetheless, “everyone who

is very related to the law of

Stenn, M.D. The former Yale

utes of walking, scientists

was anyone” wanted a beaver

another system.”

pathologist and dermatolo-

have estimated, would have

hat, Stenn writes. When the

gist moves from the evolu-

felled upright fur-covered

fashion killed off beavers

research, Stenn visited wig-

tion of human hair to hair’s

hominids with heatstroke.

in European forests, traders

makers in Japan, studied

sailed to North America,

the anthropology of hair in

effects on culture, psychol-

Unlike animal hair, which

During two years of

ogy, and global trade. By

grows on a fixed cycle and

where Native Americans

Paris, learned about furs in

the end of Hair: A Human

sheds twice a year, human

bartered pelts for pots, guns,

Montreal, and toured a wool

History, a reader might

hair follicles stagger their

rum, and metal beaver traps.

museum in Wales. Stenn, on

even be convinced that hair

growth. Moreover, each type

By about 1840, the trade had

the faculty at the School of

makes the world go ’round.

of human hair abides by its

ravaged the North American

Medicine from 1971 to 1991

Stenn begins by explain-

own calendar. A scalp hair

beaver population as well.

and the former director of

ing why we, of all primates,

shaft will grow for two to

lost most of our body hair:

six years, allowing humans

Our ancestors became naked
apes to cool their growing

Animal hair does more

skin biology at Johnson &

than keep us warm and

Johnson, now writes full time.

to wear hair cascading down

stylish. Bow makers, called

Next, he plans an illustrated

their backs or in coronas

archetiers, use horsehair and

children’s book on hair. “I’ll

and temperature-sensitive

around their heads. Eyelashes

rosin to create the ribbon on a

still keep the science in,” says

brains, which would suffer

remain short because they

violin or cello bow. (Stallions

Stenn. He may use dogs and

grow for just 30 days.
Another mammal’s
hair—sheep’s wool—shaped

{ Send notices of new books to

Yale Medicine, 1 Church Street, Suite 300, New Haven, CT 06510 or email ymm@yale.edu
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cats to demonstrate that fur
is directional. “You don’t pet
your cat from tail to head.”

T E R R Y D A G R A D I P H O T O ; O P P O S I T E PA G E , R O B E R T L I S A K P H O T O

named John Barton placed

end note

Dancing for Donation
E L E V E N C O U PL E S , including physicians,

transplant nurses, an organ recipient, and donor
advocates, danced away the night of March
18 at the Aria Banquet Facility in Prospect to
raise awareness of organ donation in a time
of organ shortages. More than 500 people at
the Dancing for Donation Gala, sponsored
by Donate Life Connecticut, watched dancers including Yale’s own Joyce Alpert, Manuel
Rodriguez and Patricia Aguayo, Bill and Christy
Asch, Gary and Deborah Desir (in photo), and
Frank and Margaret Bia, perform ballroom routines. Donations made on behalf of the teams
raised more than $45,000. The event’s grand
champions, Rodriguez and Aguayo, raised more
than $10,000. The Desirs won first place in talent, and the Bias took second place.
—John Curtis

